Phase I ascending dose trial of Type 1 Interferon (IFN -1)/ Hyaluronic Acid formulation for the early treatment of SARS-CoV2 infection (COVID-19)
Latest Information Update: 15 Mar 2022
At a glance
- Drugs Hyaluronic acid+interferon intranasal-Naris Therapeutics (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Acronyms INFINiTE-CV2
Most Recent Events
- 15 Mar 2022 New trial record